New GSK, with new ambitions for patients and shareholders
The following information relates to the formation of New GSK and how the company plans to drive growth and returns for shareholders. It is intended for those with a specific interest in this area.
GSK publishes Prospectus and Circular
We have published the Prospectus and Circular for the proposed demerger of our Consumer Healthcare business to form Haleon.
Our CEO Emma Walmsley discusses our strategy for New GSK, the new growth company positioned to create significant value for patients and shareholders from 2022 and for the next decade.
We expect to deliver a step change in performance with major new commitments to sales and profit growth including more than 5% sales CAGR 2021-26, more than 10% adjusted operating profit CAGR 2021-26 expected and an ambition to deliver more than £33 billion sales by 2031. This transformation will be enabled by New GSK’s growth engine, Vaccines and Specialty Medicines, which we expect to grow to around three-quarters of our revenue base by 2026.
At GSK, we have already delivered unprecedented change over the past four years, improving R&D, becoming a leader in Consumer Health, strengthening our leadership and transforming our commercial execution. Now, we are making our most significant corporate change in more than 20 years, setting out a new ambition for creating value for shareholders and impacting the health of over 2.5 billion people over 10 years.
New GSK Investor update
Emma Walmsley, CEO, and other members of the GLT hosted a virtual investor update on 23 June 2021. The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Scroll down to watch the event and access the presentations, transcripts, press release and other supplementary information.
Watch the event
Slides
- Full presentation slides pdf - 7.9MB
- Strategic transformation, outlook and ambitions pdf - 1.6MB
- Delivering growth: 2022-2026 and beyond pdf - 2.0MB
- Vaccines: strengthening leadership pdf - 1.8MB
- Specialty: reshaping HIV treatment and prevention pdf - 1.5MB
- Specialty: maximising high potential medicines pdf - 1.7MB
- Sustainable growth, competitive returns pdf - 1.7MB
- Closing comments pdf - 1.0MB
Epidemiology data
This pack contains estimated patients numbers for diseases relevant to GSK products and late-stage pipeline assets, in key markets.
Download epidemiology dataPDF - 3.3MB
Clinical trials summary
This pack contains a summary of our late stage clinical trials across our four key therapy areas plus opportunity driven.
Download clinical trials summaryPDF - 3.5MB
- Download speaker biographies PDF - 8.6MB
For media
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline.
Read the press release
Download media call slides
Investor contacts
United Kingdom
Tel: +44 (0)20 8047 5000
Email: GSK.Investor-Relations@gsk.com
United States
Toll free: +1 888 825 5249
Tel: +1 215 751 4000
Email: GSK.Investor-Relations@gsk.com
Media contacts
Global Headquarters (London, UK)
Tim Foley
VP, Global Corporate Media Relations
Madeleine Breckon
Director, Global Corporate Media Relations, Pharmaceuticals
Simon Moore
Director, Global Corporate Media Relations, Vaccines and Global Public Health
Tel: +44 (0)20 8047 5502
Email: corporate.media@gsk.com
USA (Philadelphia)
Kristen Neese
VP, Global Product & Pipeline Communications & US Corporate Communications
Email: kristen.x.neese@gsk.com
Kathleen Quinn
Head, US Corporate Communications
Email: kathleen.x.quinn@gsk.com
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
Go behind the science